These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Monophenolic 2-(dipropylamino)indans and related compounds: central dopamine-receptor stimulating activity. Hacksell U; Arvidsson LE; Svensson U; Nilsson JL; Wikström H; Lindberg P; Sanchez D; Hjorth S; Carlsson A; Paalzow L J Med Chem; 1981 Apr; 24(4):429-34. PubMed ID: 7265130 [TBL] [Abstract][Full Text] [Related]
24. 7-[3-(4-[2,3-Dimethylphenyl]piperazinyl)propoxy]-2(1H)-quinolinone (OPC-4392), a presynaptic dopamine autoreceptor agonist and postsynaptic D2 receptor antagonist. Yasuda Y; Kikuchi T; Suzuki S; Tsutsui M; Yamada K; Hiyama T Life Sci; 1988; 42(20):1941-54. PubMed ID: 3130534 [TBL] [Abstract][Full Text] [Related]
25. Characterization of dopamine autoreceptor and [3H]spiperone binding sites in vitro with classical and novel dopamine receptor agonists. Lehmann J; Briley M; Langer SZ Eur J Pharmacol; 1983 Mar; 88(1):11-26. PubMed ID: 6133762 [TBL] [Abstract][Full Text] [Related]
26. Activity of ibopamine on central nervous system in mice and rats. Ferrini R; Miragoli G; Sala R; Reggiani A Arzneimittelforschung; 1986 Feb; 36(2A):327-30. PubMed ID: 3707643 [TBL] [Abstract][Full Text] [Related]
27. Dopaminergic structure-activity relationships of 2-aminoindans and cardiovascular action and dopaminergic activity of 4-hydroxy, 5-methyl, 2-di-n-propylaminoindan (RD-211). Ma SX; Long JP; Flynn JR; Leonard PA; Cannon JG J Pharmacol Exp Ther; 1991 Feb; 256(2):751-6. PubMed ID: 1671601 [TBL] [Abstract][Full Text] [Related]
30. Synthesis and central dopaminergic effects of N-(4,6-dimethyl-2-pyridinyl)benzamides. Bouhayat S; Piessard S; Le Baut G; Sparfel L; Petit JY; Piriou F; Welin L J Med Chem; 1985 May; 28(5):555-9. PubMed ID: 4039368 [TBL] [Abstract][Full Text] [Related]
31. The thieno[3,2-c]pyridine and furo[3,2-c]pyridine rings: new pharmacophores with potential antipsychotic activity. New JS; Christopher WL; Yevich JP; Butler R; Schlemmer RF; VanderMaelen CP; Cipollina JA J Med Chem; 1989 Jun; 32(6):1147-56. PubMed ID: 2542551 [TBL] [Abstract][Full Text] [Related]
32. Synthesis, dopaminergic profile, and molecular dynamics calculations of N-aralkyl substituted 2-aminoindans. Andujar SA; de Angel BM; Charris JE; Israel A; Suárez-Roca H; López SE; Garrido MR; Cabrera EV; Visbal G; Rosales C; Suvire FD; Enriz RD; Angel-Guío JE Bioorg Med Chem; 2008 Mar; 16(6):3233-44. PubMed ID: 18166467 [TBL] [Abstract][Full Text] [Related]
33. Effects of nootropic drugs on dopaminergic systems in the CNS. Westermann KH; Schmidt J; Bucher U Pol J Pharmacol Pharm; 1981 Nov; 33(4):431-6. PubMed ID: 6799944 [TBL] [Abstract][Full Text] [Related]
34. Synthesis and angiotension converting enzyme inhibitory activity of L-lysyl-N-substituted glycine derivatives. Saito S; Matsui S; Fukushima S; Watanabe M; Waga T; Kajiwara Y; Shirota M; Iijima M; Kitabatake K Arzneimittelforschung; 1989 Dec; 39(12):1558-61. PubMed ID: 2560371 [TBL] [Abstract][Full Text] [Related]
35. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. Kikuchi T; Tottori K; Uwahodo Y; Hirose T; Miwa T; Oshiro Y; Morita S J Pharmacol Exp Ther; 1995 Jul; 274(1):329-36. PubMed ID: 7616416 [TBL] [Abstract][Full Text] [Related]
36. Effects of ethanol on central dopamine functions. Lai H; Carino MA; Horita A Life Sci; 1980 Jul; 27(4):299-304. PubMed ID: 7191036 [No Abstract] [Full Text] [Related]
37. Effect of repeated treatment with milnacipran on the central dopaminergic system. Rogóz Z; Margas W; Dlaboga D; Góralska M; Dziedzicka-Wasylewska M; Maj J Pol J Pharmacol; 2000; 52(2):83-92. PubMed ID: 10949109 [TBL] [Abstract][Full Text] [Related]
38. Studies on the participation of the dopaminergic system in the central effects of chronically administered antidepressant drugs. Kozyrska C; Zebrowska-Lupina I Pol J Pharmacol Pharm; 1983; 35(2):115-26. PubMed ID: 6684769 [TBL] [Abstract][Full Text] [Related]
39. A comparison of dopamine agonist action to inhibit locomotor activity and to induce stereotyped behaviour in the mouse. Bradbury AJ; Cannon JG; Costall B; Naylor RJ Eur J Pharmacol; 1984 Oct; 105(1-2):33-47. PubMed ID: 6541588 [TBL] [Abstract][Full Text] [Related]
40. [Effect of carbidine on the dopamine and serotonin receptors of the central nervous system]. Zharkovskiĭ AM; Klassen NE; Zharkovskiĭ TA Biull Eksp Biol Med; 1985 Jun; 99(6):700-2. PubMed ID: 2861866 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]